OBJECTIVE: To investigate whether systemic therapy with 1-alpha,25-dihydroxyvitamin D(3) (vitamin D(3) [hereinafter, VD(3)]) prevents tumor formation in a hamster buccal pouch model of carcinogenesis. DESIGN: Randomized trial in which a known carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), was applied to the buccal pouch of 40 hamsters. Animals were randomized to receive systemic VD(3) or no treatment and killed at 2, 6, and 14 weeks after the initiation of DMBA exposure. SETTING: Academic medical center. SUBJECTS: Forty male golden Syrian hamsters, aged 5 to 6 weeks, were used. INTERVENTIONS: A dose of 0.25 mug/kg of VD(3) via intraperitoneal injection was given to 20 animals 3 times per week. Of the remaining 20 control animals, 5 received placebo vehicle injection, and 15 received no further treatment. MAIN OUTCOME MEASURES: Timing, size, and number of tumors that developed in the 2 groups. RESULTS: Only 1 hamster treated with VD(3) developed a confirmed neoplasm compared with 7 of the control animals (P < .01). The mean +/- SD total diameter of gross lesions per animal in the VD(3)-treated group was 1.2 +/- 1.9 mm compared with 6.8 +/- 6.6 mm in the control group (P = .03). The time to onset of lesion formation was significantly delayed in those animals treated with VD(3), with a mean +/- SD time to development of 13.4 +/- 0.9 weeks, while the control animals developed lesions at 11.2 +/- 1.7 weeks (P = .02). CONCLUSIONS: Systemic VD(3) therapy delays carcinogenesis in the hamster buccal pouch model. Further investigation into the mechanisms through which VD(3) inhibits carcinogenesis may lead to development of effective chemopreventive agents to combat head and neck cancer.
OBJECTIVE: To investigate whether systemic therapy with 1-alpha,25-dihydroxyvitamin D(3) (vitamin D(3) [hereinafter, VD(3)]) prevents tumor formation in a hamster buccal pouch model of carcinogenesis. DESIGN: Randomized trial in which a known carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), was applied to the buccal pouch of 40 hamsters. Animals were randomized to receive systemic VD(3) or no treatment and killed at 2, 6, and 14 weeks after the initiation of DMBA exposure. SETTING: Academic medical center. SUBJECTS: Forty male golden Syrian hamsters, aged 5 to 6 weeks, were used. INTERVENTIONS: A dose of 0.25 mug/kg of VD(3) via intraperitoneal injection was given to 20 animals 3 times per week. Of the remaining 20 control animals, 5 received placebo vehicle injection, and 15 received no further treatment. MAIN OUTCOME MEASURES: Timing, size, and number of tumors that developed in the 2 groups. RESULTS: Only 1 hamster treated with VD(3) developed a confirmed neoplasm compared with 7 of the control animals (P < .01). The mean +/- SD total diameter of gross lesions per animal in the VD(3)-treated group was 1.2 +/- 1.9 mm compared with 6.8 +/- 6.6 mm in the control group (P = .03). The time to onset of lesion formation was significantly delayed in those animals treated with VD(3), with a mean +/- SD time to development of 13.4 +/- 0.9 weeks, while the control animals developed lesions at 11.2 +/- 1.7 weeks (P = .02). CONCLUSIONS: Systemic VD(3) therapy delays carcinogenesis in the hamster buccal pouch model. Further investigation into the mechanisms through which VD(3) inhibits carcinogenesis may lead to development of effective chemopreventive agents to combat head and neck cancer.
Authors: Katelyn D Bothwell; Tatiana Shaurova; Mihai Merzianu; Amritha Suresh; Moni A Kuriakose; Candace S Johnson; Pamela A Hershberger; Mukund Seshadri Journal: Cancer Prev Res (Phila) Date: 2015-06-22
Authors: David D Walker; Travis D Reeves; Anna-Maria de Costa; Corinne Schuyler; M Rita I Young Journal: Cytokine Date: 2012-03-24 Impact factor: 3.861
Authors: D Gregory Farwell; Jeremy D Meier; Jesung Park; Yang Sun; Heather Coffman; Brian Poirier; Jennifer Phipps; Steve Tinling; Danny J Enepekides; Laura Marcu Journal: Arch Otolaryngol Head Neck Surg Date: 2010-02
Authors: Hannah Arem; Stephanie J Weinstein; Ronald L Horst; Jarmo Virtamo; Kai Yu; Demetrius Albanes; Christian C Abnet Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-28 Impact factor: 4.254
Authors: Matthew Lam; Abhijit J Chaudhari; Yang Sun; Feifei Zhou; Allison Dobbie; Regina F Gandour-Edwards; Steve P Tinling; D Gregory Farwell; Wayne L Monsky; K Kirk Shung; Laura Marcu Journal: J Ultrasound Med Date: 2013-10 Impact factor: 2.153
Authors: Murat Yildirim; Kyle P Quinn; James B Kobler; Steven M Zeitels; Irene Georgakoudi; Adela Ben-Yakar Journal: Scanning Date: 2016-04-25 Impact factor: 1.932
Authors: Florian Bochen; Benedikt Balensiefer; Sandrina Körner; Jörg Thomas Bittenbring; Frank Neumann; Armand Koch; Klaus Bumm; Anke Marx; Silke Wemmert; Georgios Papaspyrou; David Zuschlag; Jan Philipp Kühn; Basel Al Kadah; Bernhard Schick; Maximilian Linxweiler Journal: Oncoimmunology Date: 2018-07-23 Impact factor: 8.110